SIP aims to become world-classbio-medicine base
In recent years, SIP has been making great efforts to promote the development of bio-medicine industry and technological innovation, aiming at becoming a world-class base for innovations and business startups in the bio-medicine sector.
Currently, SIP is home to nearly 900 bio-medicine enterprises, including such Fortune 500 enterprisesas GSK,Eli Lilly and JNJ. It boasts13academicians from different countries like the United States, the UK, Canada and China, more than 50 experts under China's Thousand Talents program,and over 700 Chinese enterprises with proprietary brands. The total output value of SIP's bio-medicine industry reached more than RMB48 billion in 2016, up over 27% year-on-year.
The rapid development of the Chinese enterprises with proprietary brands is an indication of the prospect of SIP's bio-medicine industry. Innovent Biologics is the first Chinese enterprise to authorize a Fortune 500 enterprise (Eli Lilly) to promote its independently developed product in overseas market. Alphamab has 28 bio-medicinerelated product lines. Moreover, in 2015, Suzhou Genewiz Biological Science & Technology Co Ltd acquired the genome business of Beckman Coulter, a Fortune 500 enterprise based in the United States, becoming a world leading genomic service supplier.
SIP is planning to invest more than RMB10 billion to promote the development ofbio-medicine industry in the following five years. The number of SIP-based bio-medicine enterprises is expected to reach over 1,500 by 2020, with total output value of more than RMB100 billion and more than 100,000 innovative industrial talents. Then SIP will become a world-classbio-medicine development base featuring concentrated innovation factors, integrated industrial ecosystem, abundant human resources, endlessly emerging innovation achievements and huge development potentials.
June 14, 2017